Courtney Marabella

Senior Editor, OncLive®
Courtney Marabella joined the MJH Life Sciences team in 2021 and is Senior Editor for OncLive®. Prior to joining the company she worked as the Audience Development Editor for the Asbury Park Press, part of the USA Today Network. Email: cmarabella@onclive.com

Articles

Tolaney Spotlights Tailoring Therapy by Risk in HER2+ Breast Cancer

July 16th 2021

By adapting adjuvant therapy based on responses to preoperative therapy, investigators may be able to change long term outcomes for patients with HER2-positive breast cancer, creating a paradigm shift in the space.

Pevonedistat/Azacitidine Could Become New Frontline Standard for Higher-Risk MDS

July 15th 2021

David Sallman, MD, discusses the role of hypomethylating agents in the treatment of patients with higher-risk myelodysplastic syndrome, the promise of pevonedistat in this population, the hunt for biomarkers of response to treatment, and remaining areas of unmet need to address with future efforts.

Darolutamide/ADT Significantly Improves OS in Nonmetastatic CRPC, Irrespective of Crossover

July 15th 2021

Neal Shore, MD, FACS, discusses the impact of crossover from placebo to darolutamide on OS benefit in patients with nmCRPC enrolled to the ARAMIS trial, and next steps for the androgen receptor inhibitor.

Pelabresib May Represent Optimal Partner for JAK Inhibition in Myelofibrosis

July 13th 2021

Prithviraj Bose, MD, discusses data with pelabresib from the MANIFEST trial and future research directions for BET inhibition in patients with myelofibrosis.

Low Antibody-Mediated Responses to mRNA COVID-19 Vaccine Observed in CLL, Elderly Myeloma

July 13th 2021

The BNT162b2 mRNA COVID-19 vaccine may demonstrate decreased efficacy in patients with certain types of hematologic cancers, such as chronic lymphocytic leukemia and multiple myeloma.

Frontline Ibrutinib/Venetoclax Elicits Durable Responses in CLL With Undetectable MRD

July 13th 2021

Fixed-duration ibrutinib plus venetoclax produced superior progression-free survival when compared with chlorambucil plus obinutuzumab in the frontline treatment of patients with chronic lymphocytic leukemia, with durable responses observed in those who achieved undetectable minimal residual disease negativity.

Spotlighting Symptom Management Strategies, Factors to Inform Treatment Decisions in Myelofibrosis

July 13th 2021

Naveen Pemmaraju, MD, discusses approaches to adequately manage symptoms experienced by patients with myelofibrosis, challenges faced with defining disease progression, and strategies for when to initiate or delay treatment.

Abiraterone/Prednisone Combo Linked With Improvements in Fatigue and QoL, But Worsening Metabolic Changes in mCRPC

July 12th 2021

Abiraterone acetate plus prednisone should be considered as the first treatment choice for patients with newly diagnosed metastatic castration-resistant prostate cancer if fatigue is a concern.

Galinpepimut-S Plus Pembrolizumab Shows Early Activity in Advanced Ovarian Cancer

July 9th 2021

The combination of galinpepimut-S and pembrolizumab has demonstrated promising clinical immunobiological activity in patients with Wilms Tumor 1–positive, relapsed or refractory, platinum-resistant advanced metastatic ovarian cancer, according to results from an ad-hoc analysis of a phase 1/2 trial.

Bekaii-Saab Breaks Down Significant Developments in the Realm of Gastrointestinal Cancers

July 8th 2021

Tanios Bekaii-Saab, MD, spotlights the recent developments made in gastrointestinal cancers.

Pacritinib Possesses Unique Potential for Myelofibrosis With Low Platelet Counts

July 7th 2021

Ruben Mesa, MD, discusses what makes pacritinib a unique option in the myelofibrosis landscape, future efforts with the agent, and where the drug might fit into the paradigm if approved.

Menin Inhibitors Like KO-539 May Represent Next Forefront of AML Treatment

June 30th 2021

Eunice Wang, MD, discusses the KOMET-001 trial, the potential for KO-539 to address an unmet need in acute myeloid leukemia, and the future of menin inhibition in this disease.

Mason Spotlights on Surgical Implications of New Lung Cancer Developments

June 30th 2021

David P. Mason, MD, discusses new neoadjuvant and adjuvant developments in the treatment of patients with non–small cell lung cancer, as well as what those data mean from a surgical perspective.

Lopes Shines a Light on the Explosion of Targeted Therapies in Lung Cancer Treatment Arsenal

June 26th 2021

Gilberto Lopes, MD, discusses the latest developments made in the treatment of patients with non–small cell lung cancer whose tumors harbor genetic alterations and the clinical implications of recent regulatory approvals.

Telaglenastat/Cabozantinib Does Not Significantly Improve PFS in Metastatic RCC, But Future Directions Hold Promise

June 23rd 2021

Nizar Tannir, MD, FACP, discusses the results of the phase 2 CANTATA trial with telaglenastat plus cabozantinib and future research directions for the glutaminase inhibitor.

Discrepancies Between Real-World Patterns of Care and Recommendations Based on Clinical Trials Exist in MCL

June 23rd 2021

Peter Martin, MD, discusses discrepancies in real-world patterns of care for patients with MCL and what can be done to overcome them.

Sequential 177Lu-PSMA-617 Plus Docetaxel Under Examination in Metastatic Hormone-Naïve Prostate Cancer

June 22nd 2021

Arun Azad, MBBS, PhD, FRACP, discusses the rationale that inspired the launch of the UpFrontPSMA trial, and highlights past and future research directions with 177Lu-PSMA-617 in the treatment of patients with prostate cancer.

Pacritinib May Possess the Potential to Address Unmet Needs in Myelofibrosis

June 22nd 2021

For patients with myelofibrosis who have platelets counts of less than 50,000, pacritinib represents a potential therapeutic option that can fill a need that has been unmet with other approved JAK inhibitors, such as ruxolitinib and fedratinib.

Bright White Light May Offset Negative Effects of ADT in Older Men With Prostate Cancer

June 20th 2021

Tanya Dorff, MD, discusses encouraging data from a study evaluating bright white light in older patients with prostate cancer and updates from the phase ARAMIS trial.

Oncolytic Virus/CAR T-Cell Therapy Combo Shows Preclinical Potential in Solid Tumors

June 19th 2021

City of Hope has entered into a licensing agreement with Imugene Ltd. for the patents covering a combination immunotherapy that enables CD19-directed CAR T-cell therapies to target and eradicate difficult-to-treat solid tumors.